ASCO 2022 kicks off this week, and a few days ago the abstracts for most of the presentations dropped.
There’s a lot of very interesting – though in many cases very early-stage – data coming our way, and in this quick video blog I’ve shared a few thoughts on what’s going to be particularly important for biotech companies, big pharma and investors. The Evaluate Vantage team will be reporting back from the event, and we’ll keep you up to date with the highlights (and indeed lowlights).
You can listen to my full conversation about the abstract drop with investor Brad Loncar on Clubhouse. You’ll find it in the Biotech Clubhouse – just search for ASCO22.
